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Abstract
We determined the antibiotic susceptibility and genetic mechanisms of resistance in clinical strains of Acinetobacter baumannii from Istanbul,
Turkey. A total of 101 clinical strains were collected between November 2011 and July 2012. Antimicrobial susceptibility was performed
using the Vitek 2 Compact system and E-test. Multiplex PCR was used for detecting blaOXA-51-like, blaOXA-23-like, blaOXA-40-like and
blaOXA-58-like genes. ISAba1, blaIMP-like, blaVIM-like, blaGES, blaVEB, blaPER-2, aac-3-Ia and aac-6′-Ib and NDM-1 genes were detected by PCR and
sequencing. By multiplex PCR, all strains were positive for blaOXA-51, 79 strains carried blaOXA-23 and one strain carried blaOXA-40. blaOXA-51
and blaOXA-23 were found together in 79 strains. ISAba1 element was detected in 81 strains, and in all cases it was found upstream of
blaOXA-51. GES-type carbapenemases were found in 24 strains (GES-11 in 16 strains and GES-22 in 8 strains) while blaPER-2, blaVEB-1,
blaNDM-1, blaIMP- and blaVIM-type carbapenemases were not observed. Aminoglycoside modifying enzyme (aac-3-Ia and aac-6′Ib) genes were
detected in 13 and 15 strains, respectively. Ninety-seven (96%) A. baumannii strains were deﬁned as MDR and of these, 98% were
extensively drug resistant (sensitive only to colistin). Colistin remains the only active compound against all clinical strains. As seen in other
regions, OXA-type carbapenemases, with or without an upstream ISAba1, predominate but GES-type carbapenemases also appear to have a
signiﬁcant presence. REP-PCR analysis was performed for molecular typing and all strains were collected into 12 different groups. To our
knowledge, this is the ﬁrst report of GES-11 and OXA-40 in A. baumannii from Turkey.
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Introduction
Among the Acinetobacter species, the most common and
clinically signiﬁcant is Acinetobacter baumannii [1]. It is a
gram-negative, opportunistic pathogen that causes a range of
infections, including bacteraemia, pneumonia, meningitis,
urinary tract infection and wound infection. Although carba-
penems are the preferred treatment of choice for serious
Acinetobacter infections, the resistance rates have increased
dramatically over the past decade. Carbapenem resistance in
Acinetobacter species is most commonly caused by the
production of OXA-type carbapenemases (class D b-lacta-
mases) and class B metallo-b-lactamases (MBLs) [2,3]. The
OXA-type carbapenemases are comprised of four broad
groups: blaOXA-23-like, blaOXA-40-like, blaOXA-58-like and an
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intrinsic blaOXA-51-like type [4]. The most common mechanism
for A. baumannii resistance to the carbapenems is the
existence of the OXA-23 subtype [5]. The class D OXA-51--
like b-lactamases are intrinsic to A. baumannii and have been
used as a method of identiﬁcation [6]. In addition, ISAba1
insertion sequence elements have been found in A. baumannii
strains, which can enhance the expression of OXA-type
carbapenemases and mobilize them among strains [7]. All
A. baumannii strains also encode AmpC cephalosporinases
chromosomally, which can also be overexpressed by an
upstream ISAba1 element [1]. Other enzymatic mechanisms
of resistance have also been identiﬁed in A. baumannii,
including the clavulanic-acid-inhibited extended-spectrum
b-lactamases (ESBLs) (PER-1, PER-2 and VEB-1), MBLs
(VIM-1/4, VIM-2 and IMP-1, 2, 4, 5, 6) [8], GES-like enzymes
(class b-lactamases) [9] and aminoglycoside modifying enzymes
[8].
The aim of this study was to characterize the susceptibility
proﬁle and genetic mechanisms of resistance of Acinetobacter
species collected from a major teaching hospital in Turkey.
Materials and Methods
Bacterial strains and antimicrobial susceptibility testing
In this study, consecutive strains of A. baumannii (n = 101)
isolated from clinical specimens that had been collected at
Bezmialem University Hospital in Turkey between November
2011 and July 2012 were included. The isolates were obtained
from respiratory specimens (tracheal aspirates 17%, sputum
36%), wounds (21.9%), blood (19%), catheters (3%), an
abdominal specimen (0.9%), cerebrospinal ﬂuid (0.9%), pleural
ﬂuid (0.9%) and urine (0.9%). The strains were identiﬁed by
VITEK 2 (bioMerieux, Durham, NC, USA) according to the
manufacturer’s instructions. Antimicrobial susceptibility testing
was carried out using the Vitek 2 Compact system (bioMer-
ieux, Craponne, France), including colistin and tigecycline, and
conﬁrmed with the E-test. The results were interpreted
according to the Clinical and Laboratory Standards Institute
(CLSI, 2012) guidelines.
DNA extraction
Genomic DNA was obtained from bacterial suspensions grown
overnight in Luria Broth with shaking at 37°C. Bacterial
suspensions were centrifuged at 12 470 g for 5 min, and pellets
were suspended in 500 lL distilled water and subsequently
boiled for 10 min. Debris was centrifuged at 12 470 g for
5 min and 500 lL of supernatant was obtained. Five
microlitres of each supernatant were used as a template
for PCR [10].
REP-PCR analysis
REP-PCR was used in the genotyping of A. baumannii strains.
The highly conserved REP sequence is approximately 35
nucleotides long, includes an inverted repeat, and can occur in
the genome singly or as multiple adjacent copies. The primer
pair of REP 1 (5′-IIIGCGCCGICATCAGGC-3′) and REP 2
(5′-ACGTCTTATCAGGCCTAC-3′) was used [11]. A single
reaction mixture contained: 5 lL of genomic DNA, 20 pM of
each primer, 10 lL reaction buffer (Promega, Madison, WI,
USA), 3 lL of 25 mM MgCl2, 200 lM of dNTPs and 1.5 U of
Go Taq Flexi Polymerase (Promega) in a ﬁnal volume of 50 lL.
The PCR ampliﬁcation condition was as follows: initial
denaturation at 94°C for 3 min followed by 30 cycles of
45 s at 94°C, 1 min at 45.8°C and 8 min at 72°C with a ﬁnal
extension of 16 min at 72°C. The ampliﬁed DNA fragments
were separated by electrophoresis on 1.5% agarose gel with
1-kb DNA ladder (Sigma Chemicals, Ontario, Canada) as the
size marker. The ampliﬁed DNA bands were visualized
following ethidium bromide staining under UV light and the
banding patterns of each strain were captured in an UVP
bioimaging system (UVP, Upland, CA, USA). The REP-PCR
ﬁngerprints were analyzed by the Phoretix gel analysis package
(Nonlinear USA, Inc., Durham, NC, USA).
Multiplex PCR for detection of blaOXA genes
Multiplex PCR was used for detecting blaOXA-51-like, blaOXA-23--
like, blaOXA-40-like and blaOXA-58-like genes [12]. Primers used for
the detection of blaOXA genes are shown in Table 1. PCRs
were performed in a ﬁnal volume of 50 lL and included 5 lL
of genomic DNA, 20 pM of each primer, 10 lL reaction buffer
(Promega), 3 lL 25 mM MgCl2, 200 lM of each dNTPs and
1.5 U of Taq Polymerase (Promega). PCR ampliﬁcation con-
ditions were as follows: initial denaturation at 94°C for 3 min
followed by 30 cycles of 25 s at 94°C, 40 s at 52°C and 50 s at
72°C with a ﬁnal extension of 5 min at 72°C.
PCR ampliﬁcations of the ISAba1 gene, ESBLs, MBLs and
aminoglycoside-resistance genes
The primers used are shown in Table 1. A single reaction
mixture contained: 5 lL of genomic DNA, 20 pM of each
primer, 10 lL reaction buffer (Promega), 3 lL 25 mM MgCl2,
200 lL of dNTPs and 1.5 UGo Taq Flexi Polymerase (Promega)
in a ﬁnal volume of 50 lL. PCR ampliﬁcation conditions were as
follows: initial denaturation at 95°C for 5 min followed by 35
cycles of 45 s at 95°C, 45 s at 56°C for ISAba1 and blaVEB, 55°C
for blaGES, 50°C for blaPER-2, 55°C for aac-3-Ia, 54°C for aac-6′Ib,
58°C for blaVIM-like, 56°C for blaIMP-like, 57°C for blaNDM-1 and
3 min at 72°C with a ﬁnal extension of 5 min at 72°C. All PCR
results were analyzed on 1% agarose containing 0.5 mg/L
ethidium bromide, and subsequently visualized under UV light.
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PCR products were sent to Macrogen Inc., Seoul, Korea, for
sequencing by using the same primers used in PCR reactions.
Sequencing results were analysed using the alignment search
tool BLAST (http://www.ncbi.nlm.nih.gov/BLAST) and the
multiple sequence alignment program CLUSTALW (http://
www.ebi.ac.uk/Tools/msa/clustalw2/).
Results
A total of 101 non-duplicate clinical A. baumannii strains were
collected from Bezmialem University hospitals in Turkey over
a 9-month period. Most of the isolates were obtained from
respiratory specimens (tracheal aspirates 17%, sputum 36%),
followed by wounds (21.9%), blood (19%), catheters (3%), an
abdominal specimen (0.9%), cerebrospinal ﬂuid (0.9%), pleural
ﬂuid (0.9%) and urine (0.9%). Eighteen (17.8%) and 83 (82.2%)
of all isolates were determined to be originated from the
community and hospital, respectively. All patients were
hospitalized in several units: 61 patients (60.3%) in an intensive
care unit, 12 patients (11.8%) in the internal units (nephrology,
pulmonology, etc.), 20 patients (19.8%) in surgical clinics and 7
(6.9%) in paediatric intensive care unit and only one patient
(0.9%) was children. The results showed that 31.7% and 68.3%
of A. baumannii were from colonization and an infectious agent,
respectively. The diagnoses of the patients were cirrhosis
(1.6%), heart disease (6.4%), acute and chronic renal failure
(16.1%), diabetes mellitus (DM) (16.9%), malignancy (17.7%),
chronic obstructive pulmonary disease, pneumonia, respira-
tory failure, pulmonary and thoracic diseases, pneumothorax
(28.2%), trafﬁc accidents and gunshot wounds (4.1%),
cerebrovascular accident, epilepsy, brain pathologies such as
vertebral fracture (8%), and Behcet’s disease (0.8%). All strains
were identiﬁed as A. baumannii by the VITEK GNI card and
blaOXA-51 PCR for specify for the A. baumannii species.
Most of the A. baumannii strains (n = 95) were resistant to
imipenem (95%) and meropenem (94%) (Table 2). We
observed high rates of resistance to ampicillin-sulbactam
(97%), piperacillin (97%), piperacillin-tazobactam (97%), ceft-
azidime (97%), cefoparozone-sulbactam (87%), cefepime
(97%), amikacin (63%), ciproﬂoxacin (94%), levoﬂoxacin
(89%), tetracycline (70%), trimethoprim-sulphamethoxazole
(69%) and gentamicin (48%). Tigecycline and netilmicin showed
some activity against these isolates (8% and 11% susceptible,
respectively); however, colistin was the most active compound
Primers 5′?3′ Amplicon size Tm References
OXA-51 F: TAATGCTTTGATCGGCCTTG
R: TGGATTGCACTTCATCTTGG
353 52°C [12]
OXA-23 F: GATCGGATTGGAGAACCAGA
R: ATTTCTGACCGCATTTCCAT
501 [12]
OXA-24 F: GGTTAGTTGGCCCCCTTAAA
R: AGTTGAGCGAAAAGGGGATT
246 [12]
OXA-58 F: AAGTAT TGGGGCTTGTGCTG
R: CCCCTCTGCGCTCTACATAC
599 [12]
ISAba1 F: CACGAATGCAGAAGT TG
R: CGACGAATACTATGACAC
549 56°C [13]
GES F: ATGCGCTTCATTCACGCAC
R: CTATTTGTCCGTGCTCAGGA
863 56°C [14]
VEB F:ATTTCCCGATGCAAAGCGT
R: TTATTCCGGAAGTCCCTGT
542 55°C [14]
PER-2 F: ATGAATGTCATCACAAAATG
R: TCAATCCGGACTCACT
927 50°C [15]
Aac-3-Ia F: ATGGGCATCATTCGCACA
R: TCTCGGCTTGAACGAATTGT
484 55°C [16]
Aac-6-Ib F: ATGACTGAGCATGACCTT G
R: AAGGGT TAGGCAACACTG
524 54°C [16]
IMP F: CATGGTTTGGTGGTTCTTGT
R: ATAATTTGGCGGACTTTGGC
488 56°C [17]
VIM F: ATTGGTCTATTTGACCGCGTC
R: TGCTACTCAACGACTGAGCG
780 58°C [17]
NDM-1 F GAGATTGCCGAGCGACTTG
R CGAATGTCTGGCAGCACACTT
497 57°C In this study
TABLE 1. Primers used in the
ampliﬁcation of selected genes
TABLE 2. Antibiotic susceptibility rounded off to nearest
whole per cent
Antibiotics
Antibiotic susceptibility (n = 101)
% R (no.) % I (no.) % S (no.)
Ampicillin-sulbactam 97 0 3
Piperacillin 97 0 3
Piperacillin-tazobactam 97 0 3
Ceftazidime 97 0 3
Cefoparozone-sulbactam 87 6 7
Cefepime 97 0 3
Amikacin 63 2 35
Gentamicin 48 10 42
Netilmicin 11 14 75
Ciproﬂoxacin 94 3 3
Levoﬂoxacin 89 8 3
Tetracycline 70 11 19
Tigecycline 8 27 65
Colistin 0 0 100
Trimethoprim-sulphamethoxazole 69 0 31
Imipenem 95 2 3
Meropenem 94 3 3
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(100% susceptible). Ninety-seven strains (96%) were deﬁned
as MDR based on resistance to more than two antibiotic
groups (Table 2), and of these, 98% were extensively
drug-resistant as deﬁned by resistance to all drugs except ≤2
[18]. MIC50 and MIC90 values of tigecycline of isolates were
also found to be 2 and ≥8, respectively.
The molecular analysis revealed that 79 strains (78%)
carried the blaOXA-23-like gene and one strain carried a
blaOXA-40-like gene. All strains had a blaOXA-51-like gene and
importantly, 80% of these had an upstream ISAba1 element.
Sixty-six strains had blaOXA-51-like with an upstream ISAba1 and
blaOXA-23-like together. The one strain with blaOXA-40-like also
had ISAba1 upstream from blaOXA-51-like. blaGES-like genes were
detected in 24 strains (GES-11 in 16 strains, GES-22 in eight
strains). The aminoglycoside modifying enzyme gene aac-3-Ia
was identiﬁed in 13 strains, and the aac-6′-Ib gene in 15 strains.
Many of the strains (95%) carried multiple resistance deter-
minants. For example, eight strains were positive for
blaOXA-51-like with an upstream ISAba1, blaOXA-23-like, blaGES-11
and aac-6′-Ib, whereas four strains had the same combination
of resistance mechanisms but with aac-3-Ia instead of aac-6′-Ib,
and another eight strains had similar combinations but with
blaGES-22. blaOXA-58-like, blaVEB, blaPER-2, blaIMP-like, blaVIM-like
genes and blaNDM-1 were not observed.
All 101 A. baumannii strains were typed by REP-PCR.
REP-PCR results show that our isolates harboured 12
predominant genotypes (Fig. 1). Genotypes 6 and 9 (19.8%
of isolates; n = 20) were the most prevalent; 9.9, 3.96, 5.94,
9.9, 13.86, 0.99, 6.93, 1.98, 1.98 and 4.95% of strains were
clustered into genotypes 1, 2, 3, 4, 5, 7, 8, 10, 11 and 12,
respectively. Two major clusters were obtained, one corre-
sponding to groups 1 and 12 and the second to the other
groups. The highest similarity was detected between groups 3
and 4.
Discussion
Acinetobacter baumannii is an important bacterial pathogen that
causes serious infections in immunocompromised patients. It
has reemerged among the important infectious agents, espe-
cially in healthcare institutions, primarily due to the increasing
number of outbreaks with MDR strains. MDR A. baumannii is
generally deﬁned as resistance to more than two of the
following ﬁve drug classes: antipseudomonal cephalosporins
(ceftazidime or cefepime), antipseudomonal carbapenems
(imipenem or meropenem), ampicillin-sulbactam, ﬂuoroqui-
nolones (ciproﬂoxacin or levoﬂoxacin) and aminoglycosides
(gentamicin, tobramycin or amikacin) [1]. In our strains, it was
not uncommon for resistance to be observed in all ﬁve drug
classess, with susceptibility only to colistin. This is termed
extensively drug-resistant [18]. We observed no pan-
drug-resistant strains, where the bacteria are resistant to all
available antibiotics, including colistin and tigecycline. Lately,
the use of broad-spectrum cephalosporins such as ceftazidime
and cefotaxime, carbapenems and ﬂuoroquinolones has been
associated with an increase in multidrug resistance in Acinet-
obacter species [1]. For many years, carbapenems have been
considered the drug of choice to treat serious A. baumannii
infections; however, resistance has become all too frequent
around the world, including in Turkey [19].
Our work shows high rates of resistance to the carbapen-
ems (imipenem 95% and meropenem 94%). Carbapenem-resis-
tant strains of A. baumannii have been reported worldwide and
carbapenemases, MBLs and some oxacillinases are recognized
as important contributors to carbapenem resistance in
A. baumannii [20]. OXA-type carbapenemases have predom-
inated in A. baumannii, especially in worldwide outbreaks of
OXA-23 [1]. The OXA-40 group has been reported in
Portugal, Spain, Iran and the United States. Naturally occurring
OXA carbapenemases such as OXA-51-like enzymes (e.g.
OXA 64-66, OXA 68-71, OXA 78-80, OXA-82, OXA-86,
OXA-92 and OXA104-112) have been identiﬁed in A. bau-
mannii isolates worldwide. In addition, strains producing
OXA-58 derivatives were found in isolates recovered from
Italy, Belgium, France, Greece, Iran, the United States and
Argentina [21]. OXA-23, OXA-58 and OXA-51 have been
reported in Turkey [1]; however, to our knowledge, this is the
ﬁrst report of OXA-40 in a clinical A. baumannii strain from
Turkey. In our study, all strains had an intrinsic blaOXA-51-like
gene, supporting the identiﬁcation of the strains as A. bauman-
nii [22]. Importantly, an ISAba1 element was upstream of
blaOXA-51 in 80% of strains, and this combination has been
shown to confer high levels of carbapenem resistance [23]. In
fact, in 66 strains, blaOXA-51 with an upstream ISAba1 was also
FIG. 1. REP-PCR proﬁles of 101 Acinetobacter baumannii isolates.
Twelve different genotypes were determined and most of the isolates
were clustered into genotypes 6 and 9.
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associated with blaOXA-23. We also observed for the ﬁrst time
in Turkey, blaOXA-40 in one strain, and this was associated with
ISAba1 upstream of blaOXA-51. ISAba1- blaOXA-51, ISAba1-
blaOXA-51- blaOXA-23, ISAba1- blaOXA-51- blaOXA-40 combina-
tions in A. baumannii were found in a previous study [20].
As mentioned above, carbapenem resistance in A. baumannii
is most often associated with class D b-lactamases (OXA-23-
like, OXA-40-like and OXA-58-like) and MBLs. Recently, the
Ambler class A of the GES and KPC (carbapenemase) types
has also been reported in A. baumannii. GES (Guiana-
Extended-Spectrum) b-lactamases are Class A carbapenemas-
es and can confer high level resistance to carbapenems. blaGES
genes have been reported in several countries in Europe, Asia,
South America and South Africa [9]. DNA sequencing of the
blaGES genes identiﬁed in this study showed two types; GES-11
(n = 16 strains) and GES-22 (n = 8 strains). GES-11
(AFU25739.1) was previously identiﬁed in Belgium from a
Turkish patient, suggesting its possible presence in Turkey [9].
Our study conﬁrms its presence in Turkey and, at least in
patients from our institution, GES-11 is present in a consid-
erable number of our carbapenem-resistant A. baumannii
strains.
blaOXA-40 and blaGES-11 were found together in the same
strain in this study. Similar to our results, in one study from
Kuwait, blaOXA-23 and blaGES-11 genes were found together in
33 isolates [24]. The most important characteristic of the GES
family of enzymes is their ability to evolve into carbapenemases
[25]. GES and OXA-type enzymes are together responsible for
high carbapenem resistance in our strains.The OXA-40
harbouring strain was identiﬁed from an 88-year-old patient.
The patient presented at the emergency department with
discharge and redness around the PEG. A. baumannii was
isolated in pus from this case. The isolate was only susceptible
to colistin and tigecycline, moderately susceptible to merope-
nem and tetracycline, and resistant to all other antibiotics.
Tigecycline treatment of patient is admitted to intensive care
and after 17 days of hospitalization, the patient had been ex.
REP-PCR was shown to be the discriminatory power almost
as much as PFGE. REP-PCR requires less labour compared
with PFGE and analysis makes it possible to isolate a large
number. REP-PCR was conducted to determine the genomic
diversity of A. baumannii isolates [26]. Twelve genotypes were
observed. The same antibiotic susceptibility pattern and
resistance genes were found in various REP genotypes,
suggesting horizontal transfer of resistance determinants.
Treatment options for infections caused by members of the
genus Acinetobacter are limited due to increasing levels of drug
resistance and reliance on polymyxins in combinations with
other antibiotics. Colistin has become one of the most
commonly used antibiotics for the treatment of imipe-
nem-resistant gram-negative rods. The recently approved
antibiotic tigecycline has been demonstrated to have activity
against A. baumannii [20]. In another study, colistin and
tigecycline proved to be effective alternative antimicrobial
agents for treatment of carbapenem-resistant A. baumannii
[27]. The emergence of GES-type ESBLs in A. baumannii in
Kuwait suggests that the Middle East region might be a
reservoir for carbapenemase-producing A. baumannii [24].
Similarly, according to our results, Anatolia can be a reservoir
for GES-type beta lactamase-producing A. baumannii. These
results support our understanding of carbapenem resistance in
A. baumannii strains from Turkey, showing that OXA-type
carbapenemases, with or without an ISAba1 element, and
GES-type carbapenemases predominate.
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